Patents by Inventor Grace Guoying Zhou

Grace Guoying Zhou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ONCOLYTIC HERPES SIMPLEX TYPE 1 VIRUSES FOR TREATMENT OF BRAIN TUMORS
    Publication number: 20240024392
    Abstract: Disclosed herein is an oncolytic HSV-1 virus genetically engineered for treatment of brain tumors, which lacks both copies of gamma 34.5 gene and an internal inverted repeat region and is optionally incorporated with immunostimulatory and/or immunotherapeutic genes. The oncolytic HSV-1 virus exhibited superior anti-tumor activity specifically in brain tumors. A pharmaceutical composition comprising the oncolytic HSV-1 virus and a pharmaceutically acceptable carrier, and a method of treatment of a brain tumor using the same is also disclosed.
    Type: Application
    Filed: December 3, 2021
    Publication date: January 25, 2024
    Inventors: Xiaoqing CHEN, Yuanyuan LIU, Grace Guoying ZHOU
  • EXOSOMES CONTAINING MIRNAS TARGETING HER2 SYNTHESIS AND PHARMACEUTICAL COMPOSITIONS
    Publication number: 20230398144
    Abstract: Disclosed is an engineered exosome comprising a miRNA targeting human epidermal growth factor receptor 2 (HER2) synthesis and a ligand displayed on a membrane of the exosome for specific binding to a HER2 protein expressed on a cancer cell.
    Type: Application
    Filed: October 25, 2021
    Publication date: December 14, 2023
    Inventors: Xiaoqing CHEN, Lei WANG, Xusha ZHOU, Grace Guoying ZHOU
  • PHARMACEUTICAL COMPOSITIONS, KITS AND METHODS FOR TREATING TUMORS
    Publication number: 20220347243
    Abstract: Provided is a composition for treating tumors in a subject comprising a therapeutically effective amount of an exosome carrying CTLA4-targeting miRNA and a therapeutically effective amount of an oncolytic herpes simplex virus expressing an immunostimulatory agent or both an immunostimulatory agent and an anti-PD-1 antibody. Wherein an exo-motif operably links to the seed sequence of the CTLA4-targeting miRNA to enhance the packaging of the CTLA4-targeting miRNA into the exosome.
    Type: Application
    Filed: July 4, 2019
    Publication date: November 3, 2022
    Inventors: Xiaoqing Chen, Xusha Zhou, Bernard Roizman, Grace Guoying Zhou
  • Construction of oncolytic herpes simplex viruses (oHSV) obligate vector and constructs for cancer therapy
    Patent number: 11439679
    Abstract: An obligate oHSV vector comprising modified viral DNA genome is provided. A recombinant oHSV-1 construct comprising the obligate oHSV vector and a heterologous nucleic acid sequence encoding an immunostimulatory and/or immunotherapeutic agent is also provided. Compositions comprising the recombinant oHSV-1 construct can be used for treating cancers.
    Type: Grant
    Filed: September 14, 2020
    Date of Patent: September 13, 2022
    Assignee: IMMVIRA CO., LIMITED
    Inventors: Grace Guoying Zhou, Xiaoqing Chen, Xianjie Liu
  • CONSTRUCTION OF ONCOLYTIC HERPES SIMPLEX VIRUSES (oHSV) OBLIGATE VECTOR AND CONSTRUCTS FOR CANCER THERAPY
    Publication number: 20200405792
    Abstract: An obligate oHSV vector comprising modified viral DNA genome is provided. A recombinant oHSV-1 construct comprising the obligate oHSV vector and a heterologous nucleic acid sequence encoding an immunostimulatory and/or immunotherapeutic agent is also provided. Compositions comprising the recombinant oHSV-1 construct can be used for treating cancers.
    Type: Application
    Filed: September 14, 2020
    Publication date: December 31, 2020
    Inventors: Grace Guoying Zhou, Xiaoqing Chen, Xianjie Liu
  • Construction of oncolytic herpes simplex viruses (oHSV) obligate vector and constructs for cancer therapy
    Patent number: 10821140
    Abstract: An obligate oHSV vector comprising modified viral DNA genome is provided. A recombinant oHSV-1 construct comprising the obligate oHSV vector and a heterologous nucleic acid sequence encoding an immunostimulatory and/or immunotherapeutic agent is also provided. Compositions comprising the recombinant oHSV-1 construct can be used for treating cancers.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: November 3, 2020
    Assignee: IMMVIRA CO., LIMITED
    Inventors: Grace Guoying Zhou, Xiaoqing Chen, Xianjie Liu